Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38122
CAS Number:
121032-29-9
Nélarabine
Purity:
≥ 98 % (HPLC)
Synonym(s):
9-(ß-D-arabinofuranosyl)-6-méthoxy-9 H -purine-2-amine, 2-amino-9-bD-arabinofuranosyl-6-méthoxy-9 H -purine
Documents
$254.28 /25 mg
Taille
Request Bulk Quote
Informations sur le produit

Nelarabine is a potent nucleoside analog primarily utilized in the treatment of acute lymphoblastic leukemia (ALL). This compound is particularly effective in targeting T-cell malignancies, making it a critical therapeutic option for patients who have not responded to conventional treatments. Its unique structure allows for selective uptake by cancer cells, leading to the inhibition of DNA synthesis and ultimately promoting apoptosis. Researchers and healthcare professionals appreciate Nelarabine for its ability to improve outcomes in pediatric and adult patients with refractory or relapsed ALL, demonstrating significant efficacy in clinical settings.

In addition to its primary use in oncology, Nelarabine is being explored for potential applications in other hematological malignancies and as part of combination therapies. Its favorable pharmacokinetic profile and manageable side effects make it a valuable asset in cancer treatment regimens. As ongoing studies continue to unveil its full potential, Nelarabine stands out as a promising compound in the fight against aggressive forms of leukemia, offering hope to patients and clinicians alike.

Numéro CAS 
121032-29-9
Formule moléculaire
C11H15N5O5
Poids moléculaire 
297.27
Point de fusion 
211 - 213 °C
Rotation optique 
[a] 20 D
Informations générales
Numéro CAS 
121032-29-9
Formule moléculaire
C11H15N5O5
Poids moléculaire 
297.27
Point de fusion 
211 - 213 °C
Rotation optique 
[a] 20 D
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Nelarabine is widely utilized in research focused on:

  • Oncology Treatments: This compound is primarily used in the treatment of certain types of leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL). Its effectiveness in targeting cancer cells makes it a vital option for patients who have not responded to other therapies.
  • Combination Therapy: Nelarabine is often used in combination with other chemotherapeutic agents to enhance treatment efficacy. This synergistic approach can lead to improved outcomes for patients, especially in relapsed cases.
  • Clinical Trials: Researchers are actively investigating nelarabine in clinical trials to explore its potential in treating other hematological malignancies. This ongoing research aims to expand its application and improve patient care.
  • Pharmaceutical Development: The compound serves as a model for developing new purine analogs. Its unique structure provides insights into designing more effective drugs with fewer side effects.
  • Patient Management: Nelarabine's specific action on T-cells allows healthcare providers to tailor treatment plans for patients with T-ALL, addressing individual needs and improving overall management of the disease.

Citations